Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.
Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.
Market Segmentation
The global radiotheranostics market is segmented by radioisotope, application, end-user, competitive landscape, and regional distribution. Based on the radioisotope, the market is differentiated between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64, and others. By offering the market is fragmented between oncology and non-oncology. The oncology segment is further bifurcated into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and other. The non-oncology application segment is further divided between joint infections, arthritis, bone pain, and others. On the basis of end-user, the global market is segmented between hospitals & clinics, pharmaceutical & biotechnology companies, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North America, Europe, Asia Pacific, Middle east and Africa, South America.Company Profile
TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.Report Scope
In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Global Radiotheranostics Market, by Radioisotope:
- Technetium-99
- Gallium-68
- Iodine-131
- Iodine-123
- 18F
- Y-90
- Lutetium (Lu) 177
- Copper (Cu) 67
- Copper (Cu) 64
- Others
Global Radiotheranostics Market, by Application:
- Oncology
- Non-Oncology
Global Radiotheranostics Market, by End-user:
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
Global Radiotheranostics Market, by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global radiotheranostics market.Available Customizations
With the given market data, customizations are offered according to specific needs. The following customization options are available for the report:- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Radiotheranostics Market
5. Voice of Customer
5.1. Radiotheranostics Awareness
5.2. Cancer Prevalence, by Gender
5.3. Cancer Prevalence, by Age Group
5.4. Cancer Prevalence, Region
5.5. Benefits of Using Radiotheranostics
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Radiotheranostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
8.2.2. By Application (Oncology v/s Non-Oncology)
8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
8.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
8.2.3. By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
8.2.4. By Region
8.2.5. By Company (2021)
8.3. Product Market Map
9. North America Radiotheranostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
9.2.2. By Application (Oncology v/s Non-Oncology)
9.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
9.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
9.2.3. By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
9.2.4. By Country
9.3. North America: Country Analysis
9.3.1. United States Radiotheranostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Radioisotope
9.3.1.2.2. By Application
9.3.1.2.3. By End-user
9.3.2. Mexico Radiotheranostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Radioisotope
9.3.2.2.2. By Application
9.3.2.2.3. By End-user
9.3.3. Canada Radiotheranostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Radioisotope
9.3.3.2.2. By Application
9.3.3.2.3. By End-user
10. Europe Radiotheranostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
10.2.2. By Application (Oncology v/s Non-Oncology)
10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
10.2.3. By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
10.2.4. By Country
10.3. Europe: Country Analysis
10.3.1. France Radiotheranostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Radioisotope
10.3.1.2.2. By Application
10.3.1.2.3. By End-user
10.3.2. Germany Radiotheranostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Radioisotope
10.3.2.2.2. By Application
10.3.2.2.3. By End-user
10.3.3. United Kingdom Radiotheranostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Radioisotope
10.3.3.2.2. By Application
10.3.3.2.3. By End-user
10.3.4. Italy Radiotheranostics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Radioisotope
10.3.4.2.2. By Application
10.3.4.2.3. By End-user
10.3.5. Spain Radiotheranostics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Radioisotope
10.3.5.2.2. By Application
10.3.5.2.3. By End-user
11. Asia-Pacific Radiotheranostics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
11.2.2. By Application (Oncology v/s Non-Oncology)
11.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
11.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
11.2.3. By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
11.2.4. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Radiotheranostics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Radioisotope
11.3.1.2.2. By Application
11.3.1.2.3. By End-user
11.3.2. India Radiotheranostics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Radioisotope
11.3.2.2.2. By Application
11.3.2.2.3. By End-user
11.3.3. South Korea Radiotheranostics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Radioisotope
11.3.3.2.2. By Application
11.3.3.2.3. By End-user
11.3.4. Japan Radiotheranostics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Radioisotope
11.3.4.2.2. By Application
11.3.4.2.3. By End-user
11.3.5. Australia Radiotheranostics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Radioisotope
11.3.5.2.2. By Application
11.3.5.2.3. By End-user
12. South America Radiotheranostics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
12.2.2. By Application (Oncology v/s Non-Oncology)
12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
12.2.3. By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
12.2.4. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Radiotheranostics Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Radioisotope
12.3.1.2.2. By Application
12.3.1.2.3. By End-user
12.3.2. Argentina Radiotheranostics Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Radioisotope
12.3.2.2.2. By Application
12.3.2.2.3. By End-user
12.3.3. Colombia Radiotheranostics Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Radioisotope
12.3.3.2.2. By Application
12.3.3.2.3. By End-user
13. Middle East and Africa Radiotheranostics Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
13.2.2. By Application (Oncology v/s Non-Oncology)
13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
13.2.3. By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
13.2.4. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Radiotheranostics Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Radioisotope
13.3.1.2.2. By Application
13.3.1.2.3. By End-user
13.3.2. Saudi Arabia Radiotheranostics Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Radioisotope
13.3.2.2.2. By Application
13.3.2.2.3. By End-user
13.3.3. UAE Radiotheranostics Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Radioisotope
13.3.3.2.2. By Application
13.3.3.2.3. By End-user
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. SWOT Analysis: Global Radiotheranostics Market
17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)
17.1. TransCode Therapeutics, Inc.
17.2. Curium SAS
17.3. GE Healthcare Inc.
17.4. Bayer AG
17.5. Lantheus Medical Imaging, Inc.
17.6. Novartis AG
17.7. Spectrum Pharmaceuticals, Inc.
17.8. Ipsen S.A.
17.9. Actinium Pharmaceuticals, Inc. (ATNM)
17.10. Nordic Nanovector ASA
17.11. Y-mAbs Therapeutics, Inc.
17.12. Sofie Biosciences, Inc.
17.13. Terumo Corporation
17.14. Sirtex Medical Limited
17.15. Boston Scientific Corporation
(Note: The companies list can be customized based on requirements)
18. Strategic Recommendations
Companies Mentioned
- TransCode Therapeutics, Inc.
- Curium SAS
- GE Healthcare Inc.
- Bayer AG
- Lantheus Medical Imaging, Inc.
- Novartis AG
- Spectrum Pharmaceuticals, Inc.
- Ipsen S.A.
- Actinium Pharmaceuticals, Inc. (ATNM)
- Nordic Nanovector ASA
- Y-mAbs Therapeutics, Inc.
- Sofie Biosciences, Inc.
- Terumo Corporation
- Sirtex Medical Limited
- Boston Scientific Corporation
